Figure 1.

Dose–response functions were determined for the ability of chronic desipramine treatment to reduce norepinephrine transporter (NET) expression in the cerebral cortex and hippocampus, determined by ³H-nisoxetine binding (a) and SDS–polyacrylamide gel electrophoresis (PAGE)/immunoblotting with antisera against the NET (b), and to reduce immobility time in the forced-swim test (c). All measures were determined 2 days after the end of the chronic treatment period, when brain and plasma concentrations of desipramine and its metabolite desmethyldesipramine were not detectable (ie below the 25 ng detection limit of the assay). Data shown are means ± SEM of 5–6 rats per group. *p < 0.05, **p < 0.01, ***p < 0.001 vs control.